Cognito’s $105 million Series C will advance their pivotal FDA study, expand clinical neurology partnerships, and expand work past Alzheimer’s into Parkinsons and beyond.
Continue Reading
News Source: www.forbes.com
Cognito’s $105 million Series C will advance their pivotal FDA study, expand clinical neurology partnerships, and expand work past Alzheimer’s into Parkinsons and beyond.
News Source: www.forbes.com
Leave a Reply